Earnings call Divi's Laboratories posted a 25.4% YoY revenue growth for Q3 FY25, with PAT rising 64.5% YoY. Custom synthesis continues to drive growth, while backward integration via the new Kakinada ...

Shares of Divis Laboratories Ltd climbed 5 per cent in Tuesday's trade after the drugmaker's Q3 results beat the consensus on ...

Divis Laboratories is reporting earnings from the most recent quarter on August 8. Wall Street analysts predict earnings per share of INR 11.98. Follow Divis Laboratories stock price in real-time here ...

Divis Laboratories shares gained 2.05% to trade at Rs 6,237.50 in Friday's session. At 10:27 am, the stock showed positive movement. Divis Laboratories is included as one of the stocks in the ...

Pharma stocks rose in Friday's trade after a White House release suggested the US President Donald Trump signed National Defense Authorization Act for the financial year 2026. It included the ...

Divi’s Laboratories (DIVI) Q2FY26 EBITDA was a beat; 7% above our estimates led by higher CS revenues. We expect margins to improve, led by better product mix and stable raw material prices. Mgmt.

Divis Laboratories Ltd has informed BSE that it has had a successful inspection by the US-FDA from 16th to 20th June, 2014, without any observations, for its Unit-I at vill. Lingojigudem, Choutuppal ...

Earnings call Divi's Laboratories reported a 17% YoY revenue growth in Q2 FY26, driven by a record 56% contribution from custom synthesis. Margins remained resilient despite ongoing generic pricing ...

On June 6, Divis Laboratories releases figures for Q4. Wall Street analysts expect Divis Laboratories will be reporting earnings per share of INR 14.95. Follow Divis Laboratories stock price in ...